Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow REVELATION BIOSCIENCES, INC.

Get SEC filing alerts via email and in your feed for REVELATION BIOSCIENCES, INC.

REVB REVBW

REVELATION BIOSCIENCES, INC.

About REVELATION BIOSCIENCES, INC.

Revelation Biosciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapies based on its proprietary Gemini platform. Its programs target conditions such as acute kidney injury, chronic kidney disease, and post-surgical infections by harnessing innate immune response modulation. The company focuses on innovative, inflammation-rebalancing treatments, relying on strategic partnerships, licensing agreements, and third-party manufacturing to advance its pipeline toward regulatory approval and commercialization.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from REVELATION BIOSCIENCES, INC.

1
1
REVELATION BIOSCIENCES, INC. Revelation Biosciences Reports $3.0 Million Net Loss and Increased Operating Expenses for Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
REVELATION BIOSCIENCES, INC. Revelation Biosciences Reports $8.91 Million Net Loss for 2025, Plans Funding to Sustain Operations

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
REVELATION BIOSCIENCES, INC. Revelation Biosciences Reports $6.4 Million Net Loss for Nine Months Ended September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
REVELATION BIOSCIENCES, INC. Revelation Biosciences Reports $4.5 Million Net Loss, Seeks Additional Funding

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
REVELATION BIOSCIENCES, INC. Revelation Biosciences Reports $2.1 Million Net Loss and Decrease in Total Assets

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
REVELATION BIOSCIENCES, INC. Revelation Biosciences Reports $15M Net Loss and Strategic Changes in 10-K Filing

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
REVELATION BIOSCIENCES, INC. Revelation Biosciences Reports Financial Challenges, Net Loss, and Compliance Issues

Via official filing (AI summary) | over 1 year ago | 0 comments